Dapagliflozin
Dapagliflozin (CAS 461432-26-8) is a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), an integral membrane protein primarily expressed in renal proximal tubules. Acting via specific inhibition of SGLT2-mediated glucose reabsorption, dapagliflozin facilitates urinary glucose excretion, thereby regulating plasma glucose levels. It exhibits a potent EC50 of approximately 1.1 nM for human SGLT2 and shows over 1,200-fold selectivity for hSGLT2 over hSGLT1 in vitro. Preclinical studies demonstrate improved glucose tolerance, enhanced urinary glucose excretion, and reduction of hyperglycemia in diabetic animal models. Thus, dapagliflozin serves as an important investigational molecule for type 2 diabetes research.
| Physical Appearance | A yellow oil |
| Storage | Store at -20°C |
| M.Wt | 408.87 |
| Cas No. | 461432-26-8 |
| Formula | C21H25ClO6 |
| Solubility | insoluble in H2O; ≥116.6 mg/mL in EtOH; ≥15.1 mg/mL in DMSO |
| Chemical Name | (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol |
| SDF | Download SDF |
| Canonical SMILES | CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment:[1] | |
|
Cell lines |
Chinese hamster ovary cells stably expressing human SGLT2 and SGLT1 |
|
Reaction Conditions |
1.1 nM (EC50) |
|
Applications |
Dapagliflozin inhibited accumulation of radiolabeled α-methyl-D-glucopyranoside, with EC50 values of 1.1 nM for human SGLT2 (hSGLT2) and 1.4 μM for hSGLT1. |
| Animal experiment:[1] | |
|
Animal models |
Sprague-Dawley rats |
|
Dosage form |
0.1, 1.0, and 10 mg/kg Administered orally |
|
Applications |
In normal rats, a single oral dose of 0.1, 1.0, and 10 mg/kg of dapagliflozin induced respective losses of 550, 1100, and 1900 mg of glucose per 200 g of body weight over 24 h. In streptozotocin-induced diabetic rats, a single oral dose of 0.1 mg/kg of dapagliflozin resulted in a 55% reduction in blood glucose level. The above correlation of SGLT2 inhibition, glucosuria, and blood glucose-lowering effects suggest that selective SGLT2 inhibition by dapagliflozin holds promise as a viable approach to treat type 2 diabetes. |
|
Note |
The technical data provided above is for reference only. |
|
References: 1. Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Journal of Medicinal Chemistry, 2008, 51(5): 1145-1149. |
|
| Description | Dapagliflozin is a potent and selective inhibitor of hSGLT2 with EC50 of 1.1 nM, exhibiting 1200-fold selectivity over hSGLT1. | |||||
| Targets | hSGLT2 | |||||
| IC50 | 1.1 nM (EC50) | |||||
Quality Control & MSDS
- View current batch:
Chemical structure
Related Biological Data
Related Biological Data
